NASDAQ · CLYM
Climb Bio, Inc.
$10.23-$0.10 (-0.97%)
Climb Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 44.19% below the high.
Loading market information…
NASDAQ · ITOS · USD
Stock price, earnings
Quote as of Aug 29, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
iTeos Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.43% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow iTeos Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
iTeos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the discovery and advancement of immuno-oncology therapies for patients. The company's pipeline includes two principal investigational drugs: inupadenant, a small molecule designed as an antagonist of adenosine A2AR, which is currently undergoing Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT (T-cell immunoreceptor with Ig and ITIM domains), presently in Phase 1/2 clinical assessment. Furthermore, EOS-448's mechanism involves engaging the Fc gamma receptor (FcγR) to activate dendritic cells and macrophages, thereby promoting antibody-dependent cellular cytotoxicity (ADCC). Established in 2011, iTeos Therapeutics, Inc. is based in Watertown, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:46 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $11.30M-9.35% vs estimate |
| Q3 2023 | Nov 7, 2023 | -$0.90+25.0% vs estimate | $0.00-100.0% vs estimate |
|---|
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$10.23-$0.10 (-0.97%)
Climb Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 44.19% below the high.
$8.68$0.00 (0.0%)
Sage Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 7.26% below the high.
$6.47$0.00 (0.0%)
Sinovac Biotech Ltd.: Healthcare · Medical - Pharmaceuticals.
$8.44-$2.01 (-19.23%)
Big Cypress Acquisition Corp.’s quoted price sits in the lower half of its reported 52-week range, 34.57% below the high.
$3.65$0.00 (0.0%)
Revance Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.72% below the high.
$16.70+$0.05 (+0.3%)
Orchard Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 0.12% below the high.
$7.16+$0.01 (+0.14%)
G1 Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.42% below the high.
$8.05$0.00 (0.0%)
Vigil Neuroscience, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.62% below the high.
